Aflac stock: Mizuho raises target as Q3 outlook stays mixed
π Mizuho raised Aflac's price target to $112 from $107 following Q3 results and higher earnings assumptions.
π The analyst retained an Underperform rating due to uneven premium trends and reliance on capital deployment for growth.
πΊπΈ U.S. pretax adjusted earnings surged 31.5% to $493 million in the third quarter, outpacing Japan's decline.
π―π΅ Japan pretax adjusted earnings dropped 21.0% to $961 million as new premium equivalents continue to shrink.
π° Aflac released approximately $1 billion in capital via a cession of cancer reserves to Aflac Re Bermuda.
π Reported net income was sharply lower due to portfolio repositioning losses, though adjusted EPS hit $2.43.
π΅ The board declared a Q4 dividend of $0.61 per share, payable December 1 to shareholders of record on November 18.
π Aflac returned $1.1 billion total through repurchases and dividends in the third quarter.
π Mizuho raised fiscal 2026 earnings estimates by 9% to $7.70 per share with further increases expected for 2027-2028.
π Analysts anticipate modest reductions in future benefit ratios due to assumption reviews in both Japan and the U.S.
- Mizuho raised its price target to $112 from $107, citing higher earnings estimates and capital released by a Japan reinsurance transaction.
- U.S. pretax adjusted earnings rose 31.5% to $493 million in Q3, demonstrating strong operational performance in the American market.
- The company declared a fourth-quarter dividend of $0.61 per share, marking the 44th consecutive year of dividend increases.
- Aflac returned $1.1 billion through repurchases and dividends in Q3, reinforcing its commitment to capital return strategies.
- Mizuho increased fiscal 2026 earnings estimates by 9% to $7.70 per share, with further upside projected for 2027 and 2028.
- Mizuho retained an Underperform rating due to uneven premium trends and reliance on capital deployment for future growth.
- Japan pretax adjusted earnings fell 21.0% to $961 million in Q3 as new premium equivalents continue to shrink.
- Portfolio repositioning losses pushed reported net income sharply lower despite solid adjusted earnings per diluted share of $2.43.
- Analysts expect future benefit ratios to modestly reduce in both Japan and the U.S., assuming no change in business mix.